The Therapeutic Process: Preparation, Dosing Sessions and Integration
Psychedelic-Assisted Medicine: Science and Practice
Learning objectives for this lesson:
- Describe the four phases of psychedelic-assisted therapy, from screening to integration, and explain how the process differs from treatment with a daily medication.
- Compare the inner-directed MAPS approach, psychological support in psilocybin trials, the Accept, Connect, Embody model, ketamine-assisted psychotherapy and group programs such as Roots to Thrive.
- Explain what placebo-controlled trials can and cannot show about the contribution of the therapy component.
- Estimate the clinician time that a protocol requires per participant and explain what the estimate implies for cost and access.
- Describe the content of preparation, including alliance building, history taking, intentions and psychoeducation.
- Explain why consent and safety agreements are settled while the person is sober, describe Canadian requirements for consent to touch and to recording, and construct the safety arrangements for a dosing session.
- Describe the setting, team, non-directive support, monitoring and documentation of a dosing session.
- Define integration, describe integration practices and measures, and identify situations that call for referral.
- Explain, as legal information, why preparation or integration support for unauthorized use of a psychedelic listed in the Controlled Drugs and Substances Act may expose a regulated professional to legal risk, and identify the authorized routes.
This course was developed by Dr. Kiffer G. Card.
Models of Psychedelic-Assisted Therapy: Traditions, Trial Protocols and Group Programs
Introduction
Earlier lessons examined what psychedelics do: their pharmacology (Lesson 3), their effects on the brain (Lesson 4), the subjective experience and set and setting (Lesson 5), and the risks that screening reduces (Lesson 6). This lesson turns to what clinicians do. In the models described in this lesson, the drug is given on one or a few occasions inside a structured course of psychotherapy, and the meetings before and after each dosing session are part of the treatment. In one phase 3 trial of MDMA-assisted therapy, MAPP1, each participant spent about 42 hours in sessions with two therapists, 18 of them without the drug (Mitchell et al., 2021). This process is the context for the trial evidence in Lessons 8 to 10 and for the ethical standards in Lesson 12.
Learning Objectives
- 1.1 Describe the phase-based structure that most published models of psychedelic-assisted therapy share, from screening to integration, and explain how it differs from treatment with a daily medication.
- 2.1 Distinguish the psycholytic and psychedelic traditions of psychedelic therapy.
- 2.2 Describe the inner-directed approach of the MAPS treatment manual, psychological support in psilocybin trials and the Accept, Connect, Embody model, and distinguish basic support models from models that build in an established psychotherapy.
- 2.3 Describe ketamine-assisted psychotherapy and group programs such as Roots to Thrive.
- 3.1 Explain what placebo-controlled trials can and cannot show about the contribution of the therapy itself.
- 4.1 Compare published protocols by their schedules, contact time and clinician hours, and explain what the estimate implies for cost and access.
1.1 One Process in Four Phases
Contemporary protocols differ in the drug, the number of sessions and the psychological theory behind the therapy, yet most published models follow the same four phases, shown in Figure 7.1. A 2021 review of psilocybin trials found three stages of therapy around the drug, preparation, dosing and integration (Horton et al., 2021), and a 2022 systematic review found preparation and integration in almost every model it examined (Cavarra et al., 2022). Screening establishes whether a person can be treated safely (Lesson 6). Preparation builds the relationship between the person and the therapists and readies the person for the drug’s effects (Section 2). The dosing session is the supervised period of drug action (Section 3). Integration is the work, over the following days and weeks, of making sense of the experience and applying it to daily life (Section 4).
The phases overlap. Preparation continues on the morning of each dosing session, integration after one dose prepares for the next, and screening continues through preparation; in MAPP1, participants who failed an eligibility criterion during the preparatory period were withdrawn before randomization (Mitchell et al., 2021). Health Canada’s expectations for clinical trials of psychedelic-assisted psychotherapy, published on 5 December 2022, describe the same shape: enough sessions before and after drug administration to build trust, at least two therapists present during administration, the same therapists throughout a participant’s course, and check-in visits in the days and weeks after dosing, because mental health may worsen after a session (Health Canada, 2022). This arrangement, a few supervised doses inside a course of talking therapy, is what distinguishes psychedelic-assisted therapy from a daily medication (Lesson 1).
2.1 Two Historical Traditions
Mid-twentieth-century clinicians combined psychedelics with psychotherapy in two broad ways, whose history at Weyburn and Hollywood Hospital Lesson 2 traced. Garcia-Romeu and Richards (2018) distinguish psycholytic approaches, which used low doses, from psychedelic approaches, which used high doses, and note that both often drew on psychoanalytic concepts. In psycholytic work the drug aided a talking therapy, and therapists used active techniques such as interpretation while the person was under its effects (Yaden et al., 2022). This work also contributed insights into the importance of set and setting, the person’s frame of mind and the therapeutic environment, in shaping what happens in a session (Garcia-Romeu & Richards, 2018).
Many recent trials follow the high-dose pattern: a high dose on each dosing day, attention turned inward, and few interventions by the therapists. Yaden and colleagues (2022) described supportive, non-directive psychotherapy as the default in clinical trials at the time, with more active interventions generally left out of dosing sessions, and suggested testing more active, evidence-based techniques during sessions, a modern form of the psycholytic idea that therapy can continue while the drug acts. A systematic review the same year found that several modern models had kept the non-directive stance of the early models (Cavarra et al., 2022). The flip cards define four terms that recur in this lesson.
2.2 Individual Models in Current Trials
The individual models used in recent trials lie on a spectrum. Brennan and Belser (2022) separate “basic support” models, which add no established psychotherapy from outside the psychedelic field, from models that build in an evidence-based therapy such as cognitive behavioural therapy. Table 7.1, which follows the account of ketamine-assisted psychotherapy and group programs, summarizes all six models.
2.2.1 The Inner-Directed MAPS Approach
The treatment manual for the MAPS trials of MDMA-assisted therapy for post-traumatic stress disorder (PTSD) describes “a largely non-directive method” (Mithoefer, 2017). In its version 8.1 of August 2017, non-drug sessions last 60 to 90 minutes and MDMA sessions 6 to 8 hours, both with two co-therapists, “generally one female and one male.” Safety comes before the scientific goals of a study; preparation, setting and the therapeutic alliance are essential; therapists follow the participant’s unfolding experience, favouring invitation over direction; and the participant is encouraged to trust their “inner healing intelligence,” so that the participant, and neither the drug nor the therapists, is treated as the source of healing. Music, breathing and touch, used only with consent, support the experience, and integration is “an essential and ongoing process.” The manual locates non-directiveness in “the timing of interventions”: therapists allow time for the person’s own process, may later offer direction as collaborative inquiry, and may need to be more assertive if a participant becomes agitated and unsafe (Mithoefer, 2017).
The MAPP1 phase 3 trial used this method with 90 participants. Each received three 90-minute preparatory sessions with a two-person therapist team, three 8-hour experimental sessions about four weeks apart, and three 90-minute integration sessions after each, the first on the following morning, over 18 weeks. Every therapist held at least a master’s degree, one member of each team was licensed to provide psychotherapy, and therapists completed a 15-hour online course, a five-day course, three days of experiential learning, a day of role play and 52 hours of supervision (Mitchell et al., 2021). Lesson 9 examines the results and the regulatory decision that followed.
The approach has critics. Brennan and Belser (2022) note that basic support models leave interventions loosely specified and may rely on the assumption of an inner healing intelligence, which they describe as having “yet to be subjected to empirical scrutiny”; they also disclose that they developed a competing model while working for a psychedelic drug company. At the Food and Drug Administration’s advisory committee meeting on 4 June 2024, members cited “minimal evidence that supports the benefit of the psychological approach” (Pharmaceutical Executive, 2024).
2.2.2 Psychological Support in Psilocybin Trials
The Johns Hopkins psilocybin trials use a similar approach that their investigators call psychological support. In the 2016 trial in people with life-threatening cancer, each participant met the two session monitors on a mean of 3.0 occasions, for 7.9 hours, before the first session, to discuss meaningful aspects of their life and build rapport. During sessions the monitors were “nondirective and supportive” and encouraged participants to “trust, let go and be open,” and later meetings focused on new thoughts and feelings (Griffiths et al., 2016). The monitors, trained by the clinical psychologist William Richards, ranged in formal clinical training from none to clinical psychologist. In the 2021 Hopkins trial in major depressive disorder, the support amounted to about 11 hours, 8 of them in preparation (Davis et al., 2021). Canadian trials work to a different staffing standard: Health Canada expects trial therapists to be trained in evidence-informed protocols and licensed where applicable, with unlicensed members supervised directly by a licensed therapist (Health Canada, 2022), a question Lesson 12 develops.
2.2.3 The Accept, Connect, Embody Model
The Imperial College London trial that compared psilocybin with the antidepressant escitalopram for moderate to severe depression developed the Accept, Connect, Embody (ACE) model during the trial (Murphy et al., 2022). Drawing partly on acceptance and commitment therapy and on psychological flexibility, the capacity to stay in contact with difficult thoughts and feelings while acting on one’s values, it emphasizes trust in the guides, accepting difficult emotions that the person would usually avoid, connecting to meaning, values, self and others, and mindful awareness of bodily experience (Watts & Luoma, 2020, as summarized by Murphy et al., 2022).
Each participant had two guides, one of whom could be a clinical trainee working with an experienced professional, and about 35 to 40 hours of contact, 16 of them on two dosing days three weeks apart, with the schedule shown in Figure 7.1; the guides had monthly group supervision. Participants in the escitalopram arm received the same support with a 1 mg dose of psilocybin, so the trial compared the drugs while holding the therapy constant (Murphy et al., 2022). Lesson 8 examines its results.
2.2.4 Basic Support and Models That Add an Established Therapy
Brennan and Belser (2022) classify the MAPS approach and the Hopkins cancer trial as basic support. Their examples of added therapies include psilocybin with cognitive behavioural therapy for smoking cessation (Johnson et al., 2014), with motivational enhancement and cognitive behavioural therapy for alcohol use disorder (Bogenschutz & Forcehimes, 2017), with acceptance and commitment therapy for depression (Guss et al., 2020) and with brief supportive-expressive group therapy for demoralization related to AIDS (Anderson et al., 2020). In their comparison, basic support protects the participant’s freedom to make their own meaning and needs fewer credentialed staff, while added therapies specify interventions more clearly and give therapists a more developed training framework.
2.3 Ketamine-Assisted Psychotherapy and Group Programs
As of October 2026, outside clinical trials, Special Access Program authorizations and section 56 exemptions, the main psychedelic-like drug that clinicians in Canada can lawfully use in therapy is ketamine, which is marketed in Canada as an anaesthetic and which physicians can prescribe off-label (Drug Product Database, 2026). Dames and colleagues (2022) described it as a legal “widely available psychedelic-like medicine.”
2.3.1 Ketamine-Assisted Psychotherapy
Dore and colleagues (2019) described ketamine-assisted psychotherapy in three private practices in the United States, contrasting it with intravenous ketamine for treatment-resistant depression given without psychotherapy, where the drug’s psychedelic effects are treated as unwanted side effects. In ketamine-assisted psychotherapy, ketamine is given without intravenous access, in the office or with supervised use at home, and its psychedelic effects are used within the therapy. The authors reported decreases in depression and anxiety among 235 patients, from routine practice without a control group. A 2026 scoping review of ketamine or esketamine used with psychotherapy for depression identified 47 studies, of which 4 were randomized controlled trials and most were observational studies or case reports (Swainson et al., 2026), so the evidence for ketamine-assisted psychotherapy rests mainly on early, uncontrolled studies. Lesson 8 examines the trial evidence for ketamine and esketamine. In Alberta, the licensing regime for psychedelic drug treatment services, in force since 16 January 2023, covers ketamine used in psychedelic-assisted psychotherapy and exempts ketamine used outside it (Government of Alberta, 2025).
2.3.2 Group Programs: Roots to Thrive
Roots to Thrive, a non-profit health care practice in Nanaimo, British Columbia, began in 2018 as a quality improvement initiative and became a non-profit clinical service in 2021. Its 12-week program combines a weekly large-group session with a small-group session, in cohorts of 20 to 40 people divided into small groups of 6 to 9 that keep the same members throughout, with about one facilitator for every three or four participants. Three ketamine sessions, given sublingually or by intramuscular injection, take place in the middle weeks in a ceremonial group format with a shared playlist, and a physician oversees screening, dosing and safety. The authors describe the community of practice, the weekly group in which members witness one another’s process, as the program’s primary mechanism of change (Dames et al., 2025). As of October 2026, its website lists group and individual programs and clinician training, and no psilocybin program (Roots to Thrive, 2026).
The published evaluations of its ketamine program are non-randomized, and the two that report symptom outcomes concern health care workers. A cohort report on 94 health care providers with PTSD, depression or anxiety found that at the end of the program, among those who had screened positive for each problem, 91 percent had improved in anxiety, 79 percent in depression and 92 percent in work and life functioning, and that 86 percent of those who had screened positive for PTSD screened negative (Dames et al., 2022). A chart review of 448 ketamine sessions in four cohorts found sublingual and intramuscular ketamine well tolerated; the 128 participants included 29 who took part in two cohorts, which is why the sessions number more than three per person (Tsang et al., 2023). The 2025 protocol paper reports more than 750 participants in 14 cohorts between 2020 and 2024 and lists “the absence of randomized control comparisons” among its limitations (Dames et al., 2025). A qualitative study published in July 2026 described a related Roots to Thrive program in which 25 people with a terminal diagnosis, in four cohorts between November 2021 and November 2022, took part in six to eight weekly virtual community of practice sessions and an in-person group psilocybin session, the first two cohorts under section 56 exemptions (Tsang et al., 2026). Lesson 10 returns to Roots to Thrive in the context of addiction.
3.1 What Trials Can and Cannot Tell Us About the Therapy
Which of the individual approaches should be the default is disputed. Yaden and colleagues (2022) argue for cognitive behavioural approaches, including acceptance and commitment therapy, because they avoid cultural insensitivity, make few speculative assumptions about the mind and have the largest evidence base outside psychedelic therapy. Burton and colleagues (2022) reply that no approach can claim default status before evidence is collected and that psychoanalytic therapy also has supporting evidence, and they noted that at the time no comparative studies of psychotherapy platforms had been conducted in the field of psychedelics. A 2026 meta-analysis of 23 trials in depression and anxiety found that only three used protocols derived from evidence-based psychotherapies, too few to test whether the type of therapy affects outcomes (Lindegaard & Käll, 2026), so research on this question is at an early stage and evolving. Table 7.1 sets the six models side by side, and the box after it explains why placebo-controlled trials cannot settle the question.
Table 7.1. Six models of psychedelic-assisted therapy, with their structure, the therapist’s stance and what the published evidence can show about the therapy component.
| Model | Example and source | Structure | Therapist stance | Evidence about the therapy |
|---|---|---|---|---|
| MAPS inner-directed | MAPP1, MDMA for PTSD (Mitchell et al., 2021) | 3 preparatory, 3 dosing and 9 integration sessions; two co-therapists | Non-directive; inner healing intelligence; touch only with consent | Same therapy in both arms, so not tested |
| Psychological support | Hopkins psilocybin (Griffiths et al., 2016) | About 8 hours of preparation, two dosing sessions, follow-up meetings | Nondirective and supportive | Not compared with other support |
| ACE | Imperial psilocybin (Murphy et al., 2022) | About 5 hours of preparation, two dosing days, next-day integration | Informed by acceptance and commitment therapy | Alliance predicted outcome in 30 participants |
| Added evidence-based therapy | Psilocybin with cognitive behavioural therapy for smoking (Johnson et al., 2014) | Structured therapy around dosing sessions | Structured and goal-oriented | No head-to-head comparison |
| Ketamine-assisted psychotherapy | Three practices in the United States (Dore et al., 2019) | Sublingual or intramuscular ketamine within psychotherapy | Varies by practice | Uncontrolled data from 235 patients |
| Group community of practice | Roots to Thrive, Nanaimo (Dames et al., 2025) | 12 weekly groups with three ketamine sessions | Facilitator pairs; peer witnessing | Non-randomized evaluations; outcomes reported in health care workers |
What trials can and cannot tell us about the therapy
In a placebo-controlled trial such as MAPP1 or the Imperial trial, both groups receive the same preparation, session support and integration. The difference between groups therefore estimates the added effect of the drug when given with that therapy. It does not estimate the effect of the therapy, and it does not show whether a different therapy, or less therapy, would produce the same result. Reviews that compare depression trials offering different amounts of therapy have reached mixed results: a 2025 meta-analysis of 16 psilocybin studies found no association between therapy hours and outcome (Hultgren et al., 2025), while a 2026 meta-analysis of 12 controlled trials linked more hours of preparation with larger reductions in depressive symptoms (Florineth et al., 2026), and the authors of both ask that their findings be read with caution.
An observational study from British Columbia shows the size of the gap. In a retrospective analysis of a 12-week pilot of the Roots to Thrive group program with 57 health care providers, of whom 38 chose to add three ketamine sessions, depression, anxiety and PTSD scores fell in the whole group; reductions were larger among those who received ketamine, but the difference was not statistically significant (Tsang et al., 2024). Participants chose whether to receive ketamine and the sample was small, so the study cannot separate the contributions of drug and group. That would require trials that compare therapy models, or vary the amount of therapy, while holding the drug constant.
4.1 Comparing Protocols and Clinician Time
Dames and colleagues (2022) argue that a group model reduces cost and increases capacity and access. The two tools that follow examine the time side of that argument; Lesson 12 develops the course’s view of equitable access and the counter-arguments.
Interactive 7.1 draws the week-by-week schedule of a protocol. Start from a published protocol, change the sessions, spacing or staffing, and read the checklist, which compares your protocol with Health Canada’s 2022 expectations for trials and with common practice.
Choose a published protocol or build your own. The schedule below is drawn week by week; it simplifies the published protocols, which also include screening visits and assessments.
Interactive 7.1 shows when things happen but not how much clinician time they take. Equation 7.1 estimates that time per participant: clinician hours in non-dosing sessions plus clinician hours in dosing sessions, divided by the number of participants who share the clinicians.
Worked Example 7.1. In MAPP1, each participant had 12 non-dosing sessions of 90 minutes, so N = 12 × 1.5 = 18 hours, and three dosing sessions of 8 hours, all with two therapists (Mitchell et al., 2021; Mithoefer, 2017). The participant spent 18 + 3 × 8 = 42 hours in sessions, and H = [2 × 18 + 2 × 3 × 8] ÷ 1 = 84 clinician hours, 57 percent of them in dosing sessions. A Roots to Thrive participant attends 12 weekly sessions of about 2 hours and three ketamine sessions of about 4 hours, close to the authors’ estimate of about 40 hours in total (Dames et al., 2022). With about one facilitator per 3.5 participants, H = [1 × 24 + 1 × 3 × 4] ÷ 3.5 = 10.3 facilitator hours, about one-eighth of the MAPP1 figure, leaving out the physician and nurses at ketamine sessions. Use Calculator 7.1 to check these figures and test other staffing.
Use Calculator 7.1. (a) How many clinician hours per participant does each preset require, and what share falls in dosing sessions? (b) In the MAPP1 preset, how much time is saved if only one therapist attends non-dosing sessions? (c) In two sentences, explain why the comparison does not show which protocol is more effective.
Suggested answer: (a) MAPP1 needs 84 hours (57 percent in dosing), the Imperial arm at most about 75 (43 percent) and Roots to Thrive about 10 (33 percent). (b) 18 hours, leaving 66. (c) The protocols treated different conditions and populations with different drugs, and only two had randomized comparisons, so clinician time shows cost and capacity and says nothing about which works better.
The models of psychedelic-assisted therapy share a four-phase structure and differ in how actively the therapist works, how many people share the clinicians and what theory guides the conversation. In every model, the work that decides whether a dosing session can proceed safely happens beforehand. Section 2 examines that work: building the alliance, setting intentions, explaining what to expect and obtaining consent while the person is sober.
Key Takeaways
- 1.1 Most published protocols share four phases: screening, preparation, one or a few supervised dosing sessions, and integration. The phases overlap, since integration after one dose prepares for the next, and Health Canada’s 2022 expectations for trials describe the same shape, with sessions before and after dosing, at least two therapists during administration and check-ins afterward. A few supervised doses inside a course of talking therapy is what distinguishes the approach from a daily medication; in MAPP1 a participant spent about 42 hours in sessions, 18 of them without the drug.
- 2.1 Psycholytic therapy used lower doses as an aid to psychoanalytically oriented talking therapy, with active techniques such as interpretation during the drug state, while psychedelic therapy used high doses in a supportive setting with attention turned inward. Many recent trials follow the high-dose tradition, and some authors propose testing more active, evidence-based techniques during sessions.
- 2.2 The MAPS manual describes a largely non-directive method in which two co-therapists follow the participant’s process and the participant’s inner healing intelligence is treated as the source of healing, an assumption that Brennan and Belser (2022) noted had yet to be tested. The Hopkins psilocybin trials used similar nondirective psychological support, and the Imperial trial’s Accept, Connect, Embody model drew on acceptance and commitment therapy. Brennan and Belser separate such basic support models from models that add an established therapy such as cognitive behavioural therapy.
- 2.3 Ketamine, marketed in Canada as an anaesthetic and prescribable off-label, is, as of October 2026, the main psychedelic-like drug that clinicians can lawfully use in therapy outside trials and special authorizations, and ketamine-assisted psychotherapy uses its psychedelic effects within the therapy. Roots to Thrive in Nanaimo combines 12 weekly groups with three ketamine sessions and treats the community of practice as its primary mechanism of change. Its published evaluations report large improvements but are non-randomized, and those reporting outcomes concern health care workers.
- 3.1 Because placebo-controlled trials give both arms the same preparation, support and integration, they estimate the drug’s added effect when given with that therapy and cannot show what the therapy itself contributes, or whether a different or shorter therapy would work as well. Which therapy model should be the default is therefore disputed, a 2026 meta-analysis found too few trials to test whether the type of therapy affects outcomes, and in the Roots to Thrive pilot the contributions of drug and group could not be separated.
- 4.1 Equation 7.1 estimates clinician hours per participant from the clinicians present, the non-dosing hours and the dosing sessions, divided by the number of participants who share the clinicians. MAPP1 needed about 84 clinician hours per participant, 57 percent of them in dosing sessions, while Roots to Thrive needed about 10 facilitator hours. Fewer hours mean that more people can be treated with the same staff, but the comparison shows cost and capacity only and says nothing about effectiveness.
Reflection
A hypothetical health authority in British Columbia could fund one of two psychedelic-assisted therapy services for adults with treatment-resistant depression, if a future authorization allowed it. Option A copies an individual trial protocol: two therapists per participant, about 21.5 hours of non-dosing contact and two 8-hour dosing sessions, or about 75 clinician hours per participant. Option B is a group program: 12 weekly 2-hour groups and three 4-hour dosing sessions, with one facilitator per 3.5 participants, or about 10 facilitator hours per participant. The individual protocol was tested in a randomized trial in which both arms received the same therapy; the group model has only non-randomized evaluations, and those reporting outcomes concern health care workers. Which option would you recommend piloting, what evidence would you require before scaling it up, and what does the comparison of clinician hours not tell you?
I would pilot Option A, because its structure has been tested in a randomized trial for depression and the health authority would be delivering a protocol with known safety procedures. The trial does not, however, show that this amount of therapy is necessary, since both arms received the same support, so the pilot should be designed to learn something: for example, by randomizing participants to the full protocol or to a version with fewer non-dosing hours, with outcomes rated by blinded independent assessors.
Option B is attractive for access, because it needs about one-seventh of the clinician time. Before scaling it up I would want a randomized comparison in people with treatment-resistant depression, since its evaluations are non-randomized and its outcome reports concern health care workers, and in the pilot comparison, in which participants chose whether to add ketamine, the larger reductions with ketamine were not statistically significant. I would also want safety data on group dosing in a more unwell population.
The clinician hours show cost and capacity only. They say nothing about effectiveness, about which participants benefit, or about the hidden costs of physicians, nurses, screening and supervision.
Minimum 20 characters required.
Question 1: How was the therapy organized for each participant in the MAPP1 phase 3 trial of MDMA-assisted therapy for PTSD?
Question 2: According to Brennan and Belser (2022), what distinguishes a basic support model of psychedelic-assisted therapy?
Question 3: In a placebo-controlled trial in which both arms receive the same preparation, session support and integration, what does the difference between the arms estimate?
Question 4: Using Equation 7.1, how many clinician hours per participant does an individual protocol need with 18 non-dosing hours and three 8-hour dosing sessions, with two clinicians present throughout?
Preparation: Alliance, Intentions, Psychoeducation, Consent and Safety Plans
Content note
This section refers to sexual misconduct by therapists in a clinical trial and to suicidal thoughts as a risk discussed during consent. Support is available at any time: the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8), the Hope for Wellness Help Line for Indigenous people across Canada (1-855-242-3310) and, for anyone affected by sexual violence in British Columbia, VictimLinkBC (call or text 1-800-563-0808).
Introduction
A dosing session can last a whole day, and for much of it the person may be unable to explain what they need or weigh a new decision. What keeps the session safe and useful must therefore be settled in advance, while the person is sober: who will be in the room, what happens if the experience becomes frightening, whether and how the therapists may touch the person, and how the person gets home. Preparation is also where the relationship the person will rely on during the session is built. In the Hopkins psilocybin trial in people with cancer, it took a mean of 7.9 hours over about three meetings (Griffiths et al., 2016).
Lesson 6 covered screening, exclusion criteria and the review of medications; what follows assumes that a person has been found eligible.
Learning Objectives
- 5.1 Describe the purposes, length and typical content of preparation in published protocols, including alliance building and history taking.
- 5.2 Explain how intentions and psychoeducation prepare a person for a dosing session without promising an outcome.
- 6.1 Explain why consent for psychedelic-assisted therapy is obtained while the person is sober, and list the elements of consent set out in Canadian guidance, including consent to touch and to recording.
- 6.2 Construct the agreements and safety arrangements that a person and a therapy team make before a dosing session.
5.1 What Preparation Is For
The MAPS treatment manual describes the preparatory period as “the time to gather participant history and to begin establishing an effective therapeutic alliance,” to answer questions and to explain the logistics and approach of the sessions, and asks therapists to model the attitudes the session will need, such as unhurried pacing, curiosity about the person’s present experience and respect for their boundaries (Mithoefer, 2017). Table 7.2 compares four protocols.
Table 7.2. Preparation in four published protocols: who prepares the person, how long preparation takes and what it covers.
| Protocol | Who | How long | Main content |
|---|---|---|---|
| MAPP1, MDMA for PTSD (Mitchell et al., 2021) | The two-person therapist team who will run the dosing sessions | Three 90-minute sessions, plus a review at the start of each dosing session | Alliance and trust, guidance on responding to memories and feelings that may arise, agreements on touch and safety |
| Hopkins psilocybin in cancer (Griffiths et al., 2016) | The two session monitors present on session days | A mean of 3.0 meetings and 7.9 hours | Meaningful aspects of the person’s life, rapport, what the session will be like |
| Imperial psilocybin trial (Murphy et al., 2022) | The two guides | A telephone check-in 7 to 10 days before, then about 5 hours on the day before dosing | Trust, intentions, moving toward difficult experiences, asking for help, hand holding, the music playlist |
| Roots to Thrive group program (Dames et al., 2025) | Physician, nurses and group facilitators | Group sessions in the early weeks, a one-hour education session and a ketamine information session | Expected effects, safety procedures, session-day flow, consent, touch preferences, orientation to the room and playlist |
5.1.1 Building the Alliance
The therapeutic alliance is the working relationship between a person and their therapists: agreement on goals and tasks and a bond of trust. The MAPS manual calls a safe and positive alliance “an absolute prerequisite for treatment” (Mithoefer, 2017). Therapists introduce themselves and their experience, state that participation is voluntary and that the person’s wellbeing takes precedence over the study, and make room for the person’s reactions to screening, which can be tiring and can stir up symptoms. In the Imperial trial, the person’s feelings about asking for help were explored so that asking would be easier during the session (Murphy et al., 2022).
Across psychotherapy in general, a 2018 meta-analysis of 295 studies found a consistent association between a stronger alliance and better outcomes (Flückiger et al., 2018). In psychedelic-assisted therapy the evidence is early. Among the 30 participants who received psilocybin in the Imperial trial, a stronger alliance predicted greater emotional breakthrough and mystical-type experience during the sessions and lower depression scores at the end of the trial (Murphy et al., 2022). The sample was small and the analysis observational, and a 2022 systematic review called for more research on how the alliance affects outcomes (Cavarra et al., 2022); Lesson 5 discusses this and related findings.
5.1.2 Taking a History
Preparation continues the history taking begun at screening, now to understand the person well enough to support them through whatever arises. The MAPS manual asks for open-ended questions, feedback to the person on their test results and an invitation to share what they consider significant; people with PTSD are not pushed to describe their trauma in detail, nor discouraged from doing so (Mithoefer, 2017). In Alberta, licensed providers must have a psychiatrist direct a complete psychiatric and medical assessment, including a comprehensive history of prescription and non-prescription drug and other substance use, before treatment (Government of Alberta, 2023).
The alliance and the history give the therapists a picture of the person; the next task is to give the person a picture of the session.
5.2 Intentions and Psychoeducation
Two further tasks of preparation look ahead to the dosing session: helping the person decide what they hope to attend to, and explaining what they may experience. Both are delicate, because a person who expects a particular experience may be disappointed or frightened when something else happens.
5.2.1 Intentions
An intention is a short statement, held loosely, of what the person hopes to explore or understand; setting intentions was a primary aim of preparation in the Imperial trial (Murphy et al., 2022). The MAPS manual asks therapists to keep intentions in mind while allowing “additional, perhaps unexpected, psychic material to emerge,” and describes a veteran whose image of a “monster” inside him returned, unprompted, in a later session as a valued part of himself (Mithoefer, 2017). Bathje and colleagues (2022) suggest that integration planning also begin in preparation, with an inventory of the person’s resources, time set aside for the weeks after, and supportive people asked in advance to be available.
5.2.2 Psychoeducation
Psychoeducation is the explanation of what the drug and the session may involve. The MAPS manual asks therapists to describe the kinds of experience that may occur and to invite the person to welcome difficult emotions; participants learn diaphragmatic breathing for the anxiety some feel as the drug takes effect, and are told that the experience may continue to unfold for days or weeks, sometimes in “waves,” and that some symptoms may seem to worsen before improving (Mithoefer, 2017). The Hopkins monitors encouraged participants to “trust, let go and be open” (Griffiths et al., 2016), and the Imperial guides emphasized moving toward difficult experiences (Murphy et al., 2022). Lesson 5 discusses challenging experiences.
Psychoeducation must also be honest about what treatment can do. Alberta’s standards require the consent process to cover the experimental nature of treatment, its potential benefits and risks, the evidence about them, and reasonable alternatives (Government of Alberta, 2023), and the course’s practice standard presents psychedelic-assisted therapy as a treatment that helps some people and not others, on evidence still limited in size, blinding and duration (Lessons 8 to 10). The message that symptoms may worsen first needs a safeguard. Reporting on the June 2024 Food and Drug Administration advisory committee meeting, Pharmaceutical Executive (2024) noted that a trial participant had told the agency that her therapist encouraged her to see worsening symptoms as progress. Preparation should tell people that any worsening will be taken seriously and assessed, and how to report it.
The tabs below show how these elements are commonly sequenced, as an illustrative synthesis of the MAPS manual and the Imperial and Hopkins protocols; each program sets its own schedule.
The therapists introduce themselves, restate that participation is voluntary, review the screening results, and invite the person to talk about their life, their reasons for seeking treatment and their reactions to screening (Mithoefer, 2017; Griffiths et al., 2016).
The therapists describe possible experiences, including difficult ones, and how the team will respond. The person forms intentions, practises breathing, discusses touch, considers who will support them afterward and explores feelings about asking for help (Mithoefer, 2017; Murphy et al., 2022).
The team confirms the agreements on touch, recording, staying, safety and transport, and the next-day integration session. In the Imperial trial, the playlist was discussed in a check-in call 7 to 10 days before dosing, and participants could add three pieces of their own music (Murphy et al., 2022).
Before the dose, the therapists ask what has been on the person’s mind, address fears, and refer back to the agreements made in preparation, including touch and the person’s permission for the therapists to raise the main trauma later in the session if it has not come up on its own (Mithoefer, 2017). Medical checks before dosing are described in Section 3.
Each of these steps assumes that the person has agreed, freely and with understanding, to what will happen. Consent is the subject of the next part.
6.1 Consent Obtained While Sober
Consent to psychedelic-assisted therapy has an unusual feature: the drug changes the capacities that consent relies on. Health Canada’s 2022 expectations list the psychological risks that trial consent forms must state, including unpleasant experiences, suggestibility, disordered thoughts, destabilized mood, depression, suicidal thoughts and transference between therapists and participants, as well as increased heart rate and blood pressure (Health Canada, 2022). Suggestibility, and transference, the tendency to feel toward a therapist as one felt toward an important earlier figure, make agreements reached during a session less reliable than agreements reached beforehand.
The course’s practice standard follows: decisions about participation, touch and recording are made while the person is sober, before any drug is given, and during the session the person may withdraw or narrow any consent at any time while the team does not seek to widen it. Health Canada’s expectation that consent to touch be obtained before the drug is given “as well as in the therapeutic moment” (Health Canada, 2022) fits this standard, because the check in the moment confirms what was agreed while sober. The box below gathers the elements of consent in Canadian guidance.
Elements of consent in Canadian guidance
Health Canada’s expectations for trials (5 December 2022). Written consent is obtained before participation, and the form states physical and psychological risks. Consent for touch is obtained before dosing and again in the moment; any contact is non-intimate and non-sexual; and touch is optional and consent-based except to protect a person from imminent harm. Video recording is optional; if sessions are recorded, consent is obtained first, the protocol states the purpose of recording, how often recordings are reviewed and how long they are kept, and the participant may withdraw consent at any time (Health Canada, 2022).
Alberta’s Psychedelic Drug Treatment Services Standards (January 2023). The consent process must explain whether treatment includes therapeutic touch and how it is used, the experimental nature of treatment, its potential benefits and risks and the evidence about them, and reasonable alternatives, and it must disclose any real, potential or perceived conflict of interest in recommending psychedelic treatment over conventional treatment. Consent is also required before any device is used to monitor or record treatment, and patients have a right of access to such recordings (Government of Alberta, 2023).
6.1.1 Consent to Touch
The MAPS manual distinguishes nurturing touch, such as holding a hand, a hand on the shoulder or a hug, from focused bodywork, in which the therapist offers resistance for the person to push against to release physical tension. In preparation, the therapists make clear that there is no expectation of touch at all; if the person is open to it, they ask how it should be offered: “would you like us to do it, or to always check with you or wait until you ask for touch?” The person is asked to use the word “Stop” for any unwanted touch and told that the therapists will always obey it unless touch is needed to protect the person from physical harm (Mithoefer, 2017). In the Roots to Thrive program, touch preferences are recorded on a consent form and on a whiteboard visible to the team during sessions (Dames et al., 2025). Figure 7.2 sets out the sequence.
The rule against sexual contact is absolute; the MAPS manual requires an agreement in preparation that “any sexual behavior between therapists and participant is explicitly prohibited” (Mithoefer, 2017). The rule has been broken. On 24 May 2019, MAPS disclosed that two therapists who had treated a participant in a phase 2 MDMA trial at a site in Vancouver had committed an ethical violation: one began a sexual relationship with her at the end of 2015 or early in 2016, after her active treatment ended in October 2015, and the other reportedly became aware of it, tried unsuccessfully to stop it and did not report it. MAPS reported the matter to the Food and Drug Administration, Health Canada and ethics committees, and in March 2022 stated that it had provisionally found that the two had substantially deviated from the treatment manual during treatment (MAPS, 2019; CBC News, 2022). Lesson 9 examines the case and Lesson 12 examines power, transference and boundaries. Alberta’s standards require providers to keep a policy on the duty to report abuse of a patient and to run criminal record checks and vulnerable sector searches on staff (Government of Alberta, 2023).
6.1.2 Consent to Recording
Many trials record dosing sessions on video, for safety and to check adherence to the manual. The MAPS manual asks therapists to explore the person’s feelings about recording, to explain that recordings are used only for research or training, and to tell the person that they may ask for the cameras to be turned off for a time, a request that will be respected (Mithoefer, 2017). Health Canada makes recording optional and requires the protocol to state its purpose, review and retention (Health Canada, 2022).
Interactive 7.2 lets you apply these rules. For each item, decide whether it belongs to the consent agreed while sober, to what the person can use or withdraw during the session, or to what is never permitted.
Choose a category for each item, then select Check my answers. Categories: A, agreed while sober, before dosing; B, can be used or withdrawn during the session; C, never permitted.
Consent settles what may happen in the room. The last task of preparation is to plan for what happens if the person’s state or circumstances change, during the session and afterward.
6.2 Safety Agreements and Practical Arrangements
A safety plan in psychedelic-assisted therapy is the set of agreements and arrangements, made in advance, that cover the session day, the night after it and the following weeks. The commitments listed in the MAPS manual (Mithoefer, 2017) and the setting and follow-up requirements in Health Canada’s expectations (Health Canada, 2022) define its contents.
6.2.1 Agreements for the Session
The person agrees to refrain from harm to themselves, others and property and to stop any behaviour the therapists judge dangerous; to remain in the treatment area until the session is complete, which in many MAPS protocols included an overnight stay with an attendant and the next morning’s integration session; and to leave only when the therapists judge them stable, with transport home arranged in advance. The therapists commit to remain in the room throughout, apart from brief breaks taken one at a time, to make daily telephone contact for up to a week after each session, and to be reachable by telephone 24 hours a day in that period (Mithoefer, 2017). Health Canada expects lodging to be available when an overnight stay is safer, contingency plans for serious adverse events, and check-in visits in the days and weeks after dosing (Health Canada, 2022).
6.2.2 Suicidal Thoughts, Support People and Daily Life
Suicidal thoughts are part of the risk discussion. The MAPS manual notes that they are common in people with PTSD and may increase temporarily after sessions, calling for closer contact, longer telephone support or additional visits, and MAPP1 assessed suicidality with the Columbia Suicide Severity Rating Scale at the start of every experimental session (Mithoefer, 2017; Mitchell et al., 2021). A written plan should therefore name the people and services to contact if distress rises after a session, including the team and crisis lines, and the signs that should prompt contact. Visits by a partner or friend at the end of a session are planned with the therapists in advance, and people are advised to choose carefully with whom they share sensitive material afterward (Mithoefer, 2017). Practical arrangements complete the plan: time off work, care for dependants and a quiet day after the session.
A hypothetical 46-year-old participant in an authorized psilocybin trial for depression has completed two preparation meetings with her two guides. At the final meeting she says, “What if I lose control and embarrass myself?” and, about touch, “I don’t know yet. Maybe a hand to hold, but nothing else.” She lives alone and works shifts.
The guides explain that strong emotions and changes in perception are expected and that they will stay with her throughout, and they practise slow breathing with her. On touch, they record that she accepts hand holding only, that they will always ask before offering it, and that “stop” ends any touch. They ask whether she would like to be offered hand holding if she seems distressed and cannot speak, and she says yes, with a gentle question first. They agree who will drive her home, confirm the next-morning integration session, and give her the team’s telephone number and the 9-8-8 line. She arranges two days off work.
The guides made no promise that the session would help or be pleasant, and they did not treat her uncertainty about touch as a yes.
Using Case 7.1, write the touch agreement as it would appear in her record, in no more than five sentences. Include what she has agreed to, how touch will be offered, the stop word, what will happen if she asks during the session for a hug, and when the agreement will next be reviewed.
Suggested answer: The participant consents to hand holding only and declines all other touch, including hugs and focused bodywork. Guides will ask before offering hand holding, including by a gentle question if she appears distressed and is not speaking. The word “stop” ends any touch immediately, except where touch is needed to protect her from physical harm. A request for a hug during the session will be met with verbal support and the offer of hand holding, because a hug was not agreed while she was sober. The agreement will be reviewed in the integration session and again before any later dose.
Preparation ends when the person is informed, has consented while sober and has a plan for the session and the days after it. Section 3 follows the dosing session itself: the room, the team, the therapists’ work and how the session is monitored and recorded.
Key Takeaways
- 5.1 Preparation gathers the person’s history, begins the therapeutic alliance and explains the logistics and approach of the sessions; it ranged from three 90-minute sessions in MAPP1 to a mean of 7.9 hours in the Hopkins cancer trial and about 5 hours on the day before dosing in the Imperial trial. The MAPS manual calls a safe and positive alliance an absolute prerequisite for treatment, and in a small observational analysis of the Imperial trial a stronger alliance predicted lower depression scores. History taking uses open questions and neither pushes people with PTSD to describe their trauma in detail nor discourages them from doing so.
- 5.2 An intention is a short statement, held loosely, of what the person hopes to explore, and therapists keep it in mind while allowing unexpected material to emerge. Psychoeducation describes possible experiences, including difficult ones, teaches breathing for anxiety and warns that the experience may continue to unfold in waves. It must be honest about what treatment can do, and people are told that any worsening will be taken seriously and assessed, and how to report it.
- 6.1 The drug changes the capacities that consent relies on: suggestibility and transference make agreements reached during a session less reliable than agreements reached beforehand. Under the course’s practice standard, decisions about participation, touch and recording are made while the person is sober, and during the session consent can be confirmed, narrowed or withdrawn but never widened. Health Canada expects consent to touch before dosing and again in the moment, touch that is non-intimate and non-sexual, and optional recording with a stated purpose, review and retention; sexual contact is never permitted.
- 6.2 A safety plan sets out agreements made in advance for the session day, the night after it and the following weeks: the person agrees to avoid harm, to stay until judged stable and to go home with arranged transport, and the therapists commit to stay in the room, call daily for a week and be reachable at any hour. Because suicidal thoughts may increase temporarily after sessions, the plan names the people and services to contact, including crisis lines such as 9-8-8, and practical arrangements such as time off work complete it.
Reflection
A hypothetical participant in an authorized MDMA trial for PTSD tells her two therapists in the final preparation session: “I want you to hold my hand if I get scared, but I don’t want hugs. And I’m not sure about being filmed.” Health Canada’s 2022 expectations say that consent to touch is obtained before dosing and again in the moment, that touch is non-intimate, non-sexual and optional except to protect a person from imminent harm, and that video recording is optional, with its purpose, review and retention stated and consent that can be withdrawn. The MAPS manual asks participants to use a stop word that therapists always obey unless touch is needed to protect the participant from physical harm. Write what the therapists should say and record, and explain what they should do if, during the session, she asks to be hugged.
The therapists should thank her and confirm the touch agreement in plain words: they will offer hand holding only, and they will ask before taking her hand, including if she seems frightened and is not speaking. They should explain that saying “stop” ends any touch at once, except if they ever had to keep her from physical harm. They record that she consents to hand holding with a prior check, declines hugs and all other touch, and has been told about the stop word.
On recording, they should explain that it is optional, why the trial records sessions, who will review the videos, how often and for how long they are kept, and that she can withdraw consent or ask for the cameras to be turned off for a time. Because she is unsure, they should not record her consent as given; they can offer her time to decide before the session and document her decision when she makes it, while sober.
If she asks for a hug during the session, they should respond warmly in words, offer hand holding, and explain later that a hug was not part of what she agreed while sober. The agreement can be revisited in integration and before any later session.
Minimum 20 characters required.
Question 1: Why does the course’s practice standard require decisions about touch to be made before dosing?
Question 2: Under the MAPS manual’s convention, what happens when a participant says the agreed stop word during touch?
Question 3: Which element must the consent process include under Alberta’s Psychedelic Drug Treatment Services Standards?
Question 4: What safeguard should accompany the preparation message that some symptoms may seem to worsen before improving?
The Dosing Session: Setting, Support, Monitoring and Documentation
Introduction
The dosing session is the part of psychedelic-assisted therapy that attracts the most attention, and it is also the part in which the therapists do the least talking. A participant in the MAPP1 trial spent three 8-hour days with two therapists (Mitchell et al., 2021); a participant in the Imperial psilocybin trial spent two day-long sessions with two guides, wearing an eye mask and earphones and encouraged to direct their attention inward (Murphy et al., 2022). What happens on these days follows from the preparation described in Section 2: the agreements made while the person was sober govern touch, recording and leaving, and the relationship built in preparation is what the person relies on when the experience becomes difficult. The pharmacology that sets the length of each session was covered in Lesson 3, and the evidence on music, setting and the therapeutic relationship in Lesson 5. The emphasis here is on practice: what happens hour by hour, who does what, and what is written down.
Learning Objectives
- 7.1 Describe the course of a dosing day in published psilocybin, MDMA and ketamine protocols, from the checks before the dose to discharge.
- 7.2 Describe the physical setting, music and eyeshades used in dosing sessions and the reasons protocols give for them.
- 7.3 Describe who is present during a session, explain non-directive support, and identify when more active intervention is appropriate.
- 7.4 Describe how sessions are monitored and recorded, and explain why accurate and complete records matter for safety and for the evidence base.
7.1 The Session Day, Hour by Hour
Session days in published protocols begin with checks, centre on a long period of drug action and end with a judgement that the person can safely leave. Figure 7.3 sets two of them on a common time scale, and Table 7.3, later in this part, compares three.
7.1.1 Before the Dose
Protocols begin the day with checks that confirm the person can proceed. In MAPP1, sessions began after a 10-hour fast with a urine drug screen, a pregnancy test where applicable, the Columbia Suicide Severity Rating Scale and measurements of blood pressure, body temperature and heart rate, all immediately before the first dose, which was given at about 10:00 (Mitchell et al., 2021). In the Hopkins cancer trial, participants ate a low-fat breakfast, a urine sample confirmed abstinence from cocaine, benzodiazepines and opioids, and people who used cannabis had been asked not to use it for at least 24 hours before the session (Griffiths et al., 2016). The therapists then review the person’s intentions, fears and the agreements made in preparation (Mithoefer, 2017).
7.1.2 During the Period of Drug Action
The length of the session follows the drug. The acute effect of a 25 mg dose of psilocybin lasts about 6 hours (Murphy et al., 2022). MDMA sessions in MAPP1 lasted 8 hours, and each consisted of an initial dose followed 1.5 to 2.5 hours later by a supplemental half-dose, 80 mg and 40 mg in the first session and 120 mg and 60 mg in the second and third, which the participant could decline (Mitchell et al., 2021). In the Roots to Thrive group program, ketamine sessions take about 4 hours, and participants begin to share their experiences when the effects wane at around 90 minutes (Dames et al., 2022). Lesson 3 explains these differences in onset and duration. For most of the session, the person rests, attends inward and talks when they wish, and the therapists stay with them.
7.1.3 After the Acute Effects
As the effects subside, the person usually becomes more talkative. The MAPS manual asks therapists to offer, without pressure, a chance to describe what happened, and to leave detailed discussion for the integration sessions if the person prefers to hold the experience in silence (Mithoefer, 2017). The person is encouraged to write or draw, and in many MAPS protocols stayed overnight in the clinic with a trained attendant, whose role is to keep company and monitor the person’s state without acting as a therapist. The first integration session followed the next morning (Mithoefer, 2017; Mitchell et al., 2021).
Table 7.3. Three session days compared: who is present, how long the session lasts, the setting, what is monitored, and what follows.
| Feature | MDMA, MAPP1 (Mitchell et al., 2021; Mithoefer, 2017) | Psilocybin, Hopkins (Griffiths et al., 2016; Davis et al., 2021) | Ketamine group, Roots to Thrive (Dames et al., 2022, 2025; Tsang et al., 2023) |
|---|---|---|---|
| Who is present | Two co-therapists, generally a woman and a man; an overnight attendant | Two monitors or facilitators; physicians providing medical oversight | Physician, registered nurses, facilitator pairs and, where called for, an Elder or cultural guide |
| Length | About 8 hours, often followed by an overnight stay | A day-long session; effects measured for 6 hours | About 4 hours; effects wane at around 90 minutes |
| Setting | Private room; eyeshades, headphones, music, art supplies; video | Living-room-like room; eye mask, headphones, one music program for all | Ceremonial group; eye coverings and synchronized headphones |
| Monitoring | Blood pressure, temperature and heart rate before the dose, before the supplemental dose and at the end; suicide risk scale at the start | Blood pressure, heart rate and monitor ratings of behaviour and mood at nine time points | Blood pressure below 150/90 mmHg to proceed; rescue medications on site under physician guidance |
| Afterward | 90-minute integration session the next morning; daily telephone contact for up to a week | Meeting with the monitors the next day (mean 1.2 hours) | Integration in the small groups and in meetings after each session; no driving for 24 hours |
The table shows that the shape of the day is similar across drugs while the staffing, length and monitoring differ. The next parts examine the setting and the team in turn.
7.2 The Room, the Music and the Eyeshades
The physical setting of a dosing session is designed to let the person attend to their inner experience while remaining safe. The MAPS manual asks for a room that is private and free from interruption, quiet, comfortable, with furniture on which the person can recline or sit up and chairs for the two therapists on either side, and aesthetically pleasing, “more similar to a comfortably furnished living room than a medical facility”; it should also hold medical equipment, video equipment and a locked area for records, and the person should know what safety measures are in place (Mithoefer, 2017). The manual asks that basic cardiac life support be immediately available and advanced cardiac life support reachable reasonably quickly, and that blood pressure and heart rate can be measured readily during the session. The Hopkins trials used an “aesthetic living-room-like environment” (Griffiths et al., 2016), and Health Canada’s 2022 expectations suggest that sponsors consider a comfortable and calming room (Health Canada, 2022).
7.2.1 Music and Eyeshades
A 2022 systematic review found that dosing sessions often use music and eyeshades (Cavarra et al., 2022), and in the protocols described here the person wears eyeshades and headphones for much of the session and listens to a prepared program of music. The MAPS manual states that music is selected to support emotional experience while minimizing suggestion; the person may decline the eyeshades or headphones, may ask for silence or a change of music, and is first invited to consider whether the wish to change it is a way of avoiding the feelings the music is stirring (Mithoefer, 2017). It recommends that at least one therapist know the music well, that instrumental music is generally preferable to music with lyrics in the person’s language, and that the program suit the population’s culture. Protocols differ in how much the program is tailored: Hopkins played the same program to every participant (Griffiths et al., 2016), the Imperial trial let participants add three pieces of their own (Murphy et al., 2022), and Roots to Thrive plays one ketamine-specific playlist to the whole group through synchronized headphones (Dames et al., 2022). Lesson 5 reviews the evidence on music and outcome.
7.2.2 Turning Inward and Talking
Protocols also differ in how much conversation they expect. In the Hopkins and Imperial psilocybin trials, participants were encouraged to direct their attention inward and, in the Imperial trial, to share their experiences toward the end of the day if they wished (Griffiths et al., 2016; Murphy et al., 2022). The MAPS manual for MDMA, a drug that leaves people able to talk throughout, encourages “alternating periods of going inside, using eye shades, listening to music if you want to, and then talking to us when you feel like it” (Mithoefer, 2017). In both cases the person leads, and the therapists follow, which is the subject of the next part.
7.3 The Team and Non-Directive Support
A dosing session is staffed by a team, and each member has a defined role. The arrangements in Canadian trials follow Health Canada’s expectations; those in clinical services follow provincial rules where they exist, such as Alberta’s requirement of continuous monitoring during the altered state (Government of Alberta, 2023).
7.3.1 Who Is in the Room
Health Canada’s expectations for trials call for at least two therapists during drug administration, the same therapists throughout a participant’s course, and a licensed physician who provides medical oversight, takes responsibility for medical acts and is readily available on site for the duration of the drug’s effects (Health Canada, 2022). The MAPS manual asks that both co-therapists remain in the room until the acute effects have worn off, apart from brief breaks taken one at a time (Mithoefer, 2017), and the Hopkins facilitators likewise took short breaks one at a time while the other stayed (Davis et al., 2021). In the Imperial trial one of the two guides could be a clinical trainee working alongside an experienced mental health professional (Murphy et al., 2022). The protocols do not all state the reasons for a second therapist, but the arrangement allows one therapist to rest while the other stays, gives each a colleague to consult, and places a second person in the room as a witness, one of the protections against the boundary violations discussed in Section 2.
7.3.2 What Non-Directive Support Looks Like
The MAPS manual describes the therapists’ work as interweaving periods of interaction with periods of silent witnessing. After a silence, therapists may ask about the person’s experience to keep supportive contact; at other times, they may encourage the person to stop talking and turn inward, for example when the person has reached an impasse or seems to be talking in order to avoid something. Therapists need to be comfortable with intense emotion and to keep track of their own reactions, including feelings toward the person that may reflect transference and countertransference (Mithoefer, 2017). The box below gives examples of what this sounds like.
Non-directive support in the therapists’ words
The MAPS manual illustrates its approach with statements that therapists made in trials. At the start of a session: “We don’t want to direct this nearly as much as we want to follow and support the way it unfolds for you.” On asking for help: “Ask for support in whatever way you need, if you want us to hold your hand or hold you or if you want to talk to us.” On difficult feelings: “If difficult things come up, try to stay with them and fully experience them and use your breath to move into them as much as you can” (Mithoefer, 2017).
Each statement invites; none tells the person what they will experience or what it means. The offer of being held in the second quotation is appropriate only where that touch was agreed while the person was sober (Section 2).
7.3.3 When the Session Becomes Difficult
Non-directive support still includes action when it is needed. If a person becomes agitated and feels unsafe, the MAPS manual asks therapists to be more assertive. If severe anxiety, agitation or a risk of self-harm persists at the end of a session after a two-hour period of stabilization, the therapists may stay with the person, meet daily until the person is stable or, only in extreme conditions, arrange hospital admission; a rescue medication may be given if significant anxiety persists after all other measures have failed (Mithoefer, 2017). Lesson 6 covers de-escalation, rescue medications and emergency procedures in detail, and it reviews the serious adverse events, including suicidal behaviour, that have been reported in trials.
Interactive 7.3 places you in the role of a guide during a hypothetical session. Choose a response at each point and read the feedback before moving on.
Hypothetical scenario. Sam, aged 52, is a participant in an authorized psilocybin trial for depression. Two guides are present and a physician is on site. In preparation Sam agreed to hand holding only, with the guides asking first; the stop word is “stop”; the session is video recorded with Sam’s consent; a friend will drive Sam home.
The scenario ends with the record, because what is written during and after a session is what allows the next clinician, a regulator or a researcher to know what happened. The last part of this section turns to monitoring and documentation.
7.4 Monitoring, Discharge and Documentation
Monitoring in a dosing session has two objects: the person’s body and the person’s mental state. Documentation turns both into a record that supports the person’s care, protects the person and the staff, and supplies the data from which safety and effectiveness are judged.
7.4.1 Physical Monitoring
Classic psychedelics, MDMA and ketamine all raise blood pressure and heart rate (Lesson 6), and protocols measure them on a schedule, as Figure 7.3 showed for the Hopkins trial (Griffiths et al., 2016). In the Hopkins depression trial, one session crossed the protocol’s criterion for more frequent assessment, a diastolic blood pressure above 100 mmHg; the pressure stayed within the predetermined safety limits and resolved spontaneously during the session without medical treatment (Davis et al., 2021). MAPP1 measured blood pressure, body temperature and heart rate before each dose and at the end of the session, and it recorded transient increases in blood pressure and heart rate with MDMA and two participants whose temperature rose to 38.1 °C (Mitchell et al., 2021). In Roots to Thrive, pre-session blood pressure must be below 150/90 mmHg for the session to proceed, rescue medications for high blood pressure are kept on site under physician guidance (Dames et al., 2025), and a chart review found blood pressure elevated after 49 percent of 448 sessions, with adverse effects that were brief and resolved with rest or medication (Tsang et al., 2023). In Alberta, licensed services must monitor patients continuously during the altered state, with the medical director deciding what monitoring each patient needs (Government of Alberta, 2023).
7.4.2 Monitoring the Person’s State and Deciding When They Can Leave
Mental state is monitored too. The Hopkins monitors rated each participant’s behaviour and mood, including anxiety or fearfulness and unresponsiveness to questions, at the same nine time points (Griffiths et al., 2016). At the end of an MDMA session, the therapists combine blood pressure, pulse and temperature with the person’s self-reported distress and mental state to judge whether the person is stable and the effects have waned, and they leave only when they have concluded that the person is emotionally and medically stable (Mithoefer, 2017). Roots to Thrive asks participants not to drive for 24 hours after each session (Dames et al., 2025), and Alberta’s standards require each provider to have a safe discharge procedure that includes counselling patients about the risks of after-effects (Government of Alberta, 2023).
7.4.3 Documentation
Records serve the person’s care, accountability and research. Alberta’s standards require providers to keep, for each patient, records of the eligibility assessment, the complete psychiatric and medical assessment, the treatment plan and treatment provided, the details of the consent process including the reasons for choosing psychedelic treatment over conventional treatment, any federal authorizations, and the signed service agreement, as well as records of all reports of abuse of a patient (Government of Alberta, 2023). Trial sponsors in Canada must report serious unexpected adverse drug reactions to Health Canada, and protocols that record sessions on video must state how recordings are used, reviewed and kept (Health Canada, 2022). MAPS used session videos to rate whether therapists adhered to the manual (Mithoefer, 2017).
Incomplete records weaken the evidence. The MAPP1 authors acknowledged that safety data were collected by site therapists, which may have limited blinding, although efficacy was rated by blinded independent raters (Mitchell et al., 2021). When the Food and Drug Administration’s advisory committee reviewed MDMA-assisted therapy in June 2024, members raised concerns about bias and functional unblinding, and some researchers believed that a number of adverse events had not been reported (Pharmaceutical Executive, 2024). Lesson 9 examines these concerns. The accordion below lists what a session record should contain; it is a synthesis of the sources cited in this section.
Who was present and in what roles; the checks done (drug screen, pregnancy test where applicable, suicide risk scale, blood pressure, heart rate and temperature) and their results; a summary of the person’s stated intentions, fears and current state; and confirmation that the agreements on touch, recording and staying were reviewed.
The drug, dose, form and time, the name of the person who administered it under which authorization, and any supplemental dose with its time and the checks done before it.
Timed physical measurements; timed observations of behaviour and mood; the person’s own words where they matter, in quotation marks; and any intervention, including touch, recorded with the agreement it fell under. Breaks taken by staff are also noted.
Any adverse event with its time, severity and course; who was informed and when; what was done; and whether the event must be reported to a sponsor, regulator or provincial authority.
The final measurements, the assessment of mental state and stability, who accompanied the person or where they stayed overnight, the after-effects explained to them, and the time and place of the next contact.
A hypothetical research team in British Columbia is planning individual psilocybin sessions in a Health Canada-authorized trial. List, in five to seven sentences, the people who must be present or available during each session and the equipment and arrangements the room needs, and give the source of each requirement or practice.
Suggested answer: At least two trained therapists, the same ones who prepare and follow the participant, must be present during administration, with any unlicensed member supervised by a licensed therapist, and a licensed physician must be readily available on site for the duration of the drug’s effects (Health Canada, 2022). The room should be private, quiet and comfortable, with a couch, blankets, eyeshades, headphones and a prepared music program (Mithoefer, 2017; Griffiths et al., 2016). It needs equipment to measure blood pressure and heart rate and ready access to cardiac life support (Mithoefer, 2017). Any video recording needs consent and a protocol for use, review and retention, and records are kept locked (Health Canada, 2022; Mithoefer, 2017). Lodging for an overnight stay and a contingency plan for serious adverse events complete the arrangements (Health Canada, 2022).
When the person goes home, or wakes the next morning in the clinic, the dosing session is over, but the therapeutic process is not. Section 4 examines integration: what it means, how it is practised and measured, when a person needs more help than integration can offer, and the legal limits on preparation and integration support for psychedelic use outside authorized routes.
Key Takeaways
- 7.1 Session days begin with checks such as a urine drug screen, a suicide risk scale and measurements of blood pressure, temperature and heart rate, centre on a long period of drug action and end with a judgement that the person can safely leave. The acute effects of psilocybin last about 6 hours, MDMA sessions in MAPP1 lasted 8 hours with a supplemental half dose, and ketamine sessions at Roots to Thrive take about 4 hours. In many MAPS protocols the person stayed overnight with an attendant, and the first integration session followed the next morning.
- 7.2 The room is private, quiet and comfortable, more like a living room than a medical facility, while holding medical equipment and ready access to cardiac life support. Eyeshades, headphones and a prepared music program, selected to support emotional experience while minimizing suggestion, help the person attend inward. Protocols differ in how far the music is tailored and how much conversation they expect, but in each the person leads and the therapists follow.
- 7.3 Health Canada expects at least two therapists during administration, the same therapists throughout a participant’s course, and a licensed physician readily available on site; the second therapist also places a witness in the room, one protection against boundary violations. Non-directive support interweaves silent witnessing with interaction, and its essence lies in the timing of interventions, which follow the person’s own process. Support still includes action when needed, from more assertive guidance if the person is agitated and unsafe to extended stabilization, rescue medication or, only in extreme conditions, hospital admission.
- 7.4 Protocols measure blood pressure and heart rate on a schedule, rate behaviour and mood, and discharge the person only when the team judges them emotionally and medically stable. Records should be timed and factual, give measurements and actions, and record touch with the agreement it fell under. Incomplete records weaken the evidence, as the concerns about safety data collected by site therapists and possibly unreported adverse events in the MDMA trials showed.
Reflection
In a hypothetical authorized psilocybin session, three things happen. At 90 minutes the participant’s diastolic blood pressure reads 104 mmHg, and the protocol’s threshold for more frequent checks is a diastolic pressure above 100 mmHg. At 2.5 hours she sobs and asks one guide, “What does it mean that I keep seeing my mother as a child?” At 6.5 hours she says she feels fine and wants to take a bus home alone, although a friend was due to collect her. Describe how the two guides should respond at each point, consistent with non-directive support and the protocol, and list what the session record should contain about these three events.
At 90 minutes, the guides follow the protocol: they measure blood pressure more often, inform the physician who is on site, explain calmly to the participant what they are doing, and continue to support her quietly. They do not end the session or ask her to get up.
At 2.5 hours, they stay with her distress and avoid interpreting the image. A guide might say, “You can stay with that and notice what comes,” and offer to explore its meaning in tomorrow’s integration session. If hand holding was agreed while she was sober, they may offer it in the agreed way.
At 6.5 hours, they check her blood pressure, heart rate and mental state, remind her of the agreement that her friend would drive her, and wait with her until the friend arrives and the team judges her stable. They also explain the after-effects she may notice.
The record should include the time and value of each blood pressure reading, when the physician was informed and what was decided; the time of her distress, her words in quotation marks, the guides’ response and any touch with the agreement it fell under; and the final measurements, the stability assessment, who collected her and when, and the time of the next contact.
Minimum 20 characters required.
Question 1: How does the MAPS treatment manual describe the purpose of the music played during sessions?
Question 2: What do Health Canada’s 2022 expectations call for while a psychedelic is being administered in a trial?
Question 3: In the MAPS approach, what does the term non-directive mainly refer to?
Question 4: Which session-record entry best matches the documentation practices described in Section 3?
Integration: Meaning, Outcomes, Referral and the Legal Limits of Support
Content note
This section discusses suicidal thoughts after treatment sessions and when to seek urgent help. Support is available at any time: the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and the Hope for Wellness Help Line for Indigenous people across Canada (1-855-242-3310).
Introduction
Integration begins the morning after a dosing session and continues for weeks; in MAPP1, each participant had nine 90-minute integration sessions, three times as many hours as the preparation (Mitchell et al., 2021). People who have used psychedelics on their own also seek integration support: in the Canadian Substance Use Survey 2025, published in June 2026, 7 percent of people aged 15 and older, about 2.6 million, reported past-year use of a psychedelic, most often psilocybin (Health Canada, 2026). The section therefore ends with the legal limits on such support in Canada, explained as legal information.
Learning Objectives
- 8.1 Define psychedelic integration and describe the Synthesized Model of Integration and other models of the integration process.
- 8.2 Describe the integration practices used in published protocols and state the limits of the evidence for them.
- 8.3 Describe how clinical outcomes and integration are measured, and explain why it matters who does the rating.
- 8.4 Identify situations that call for referral or escalation of care.
- 9.1 Explain, as legal information, why a regulated professional in Canada who gives preparation or integration support for unauthorized use of a psychedelic listed in the Controlled Drugs and Substances Act may be at legal risk, and identify the authorized routes.
8.1 What Integration Means
Bathje, Majeski and Kudowor (2022) observed that integration is widely cited as very important yet often mentioned only briefly, sometimes without a working definition, and proposed a synthesis of published definitions: “Integration is a process in which a person revisits and actively engages in making sense of, working through, translating, and processing the content of their psychedelic experience,” gradually bringing its lessons into their life and moving toward balance within themselves and in their lifestyle, relationships and relation to the natural world. A shorter working definition is “the process by which a psychedelic experience translates into positive changes in daily life” (Frymann et al., 2022). The MAPS manual treats integration as the time to address difficulties and anchor what was learned in daily life (Mithoefer, 2017).
Bathje and colleagues (2022) identified ten well-elaborated models of integration, all published since 2017, and synthesized them in a Synthesized Model of Integration with six facets of the person: mind, cognition and emotion; the body; the spiritual and existential; relationships and community; lifestyle and action; and the natural world (Figure 7.4). The model also arranges practices along continuums, such as contemplative to expressive, and suggests a balance across them; the authors acknowledge that it needs further research. They also question the occasional suggestion that integration matters less for Indigenous peoples who use psychedelic plants within their traditions, observing that many Indigenous worldviews encourage an ongoing orientation toward balance and integration. The course treats those traditions as belonging to the communities that hold them (Lessons 2 and 12).
8.2 Integration in Practice
Published protocols share a pattern: a first session soon after the dose, further sessions and contact over the following weeks, and a mix of open conversation with work on applying the experience.
8.2.1 Timing, Format and Stance
In MAPP1, the first 90-minute integration session took place the morning after each dosing session and two more followed over three to four weeks, with daily telephone contact for up to a week (Mitchell et al., 2021; Mithoefer, 2017). The Imperial trial held a 2- to 3-hour session the next morning with optional weekly calls (Murphy et al., 2022). In Roots to Thrive, integration takes place in the small groups and in meetings after each ketamine session, and graduates can join an alumni community of practice (Dames et al., 2022, 2025).
The MAPS manual asks therapists to open each integration session by inviting the person to talk about whatever is on their mind, so that the person’s experience sets the agenda. Therapists keep their own interpretations to a minimum and let the person judge whether a comment resonates; they help with distress and changes in relationships, prepare the person for further waves of material, plan practices, and assess whether anything argues against a further dosing session (Mithoefer, 2017).
8.2.2 Practices That Consolidate Change
Recommended practices span all six facets of Figure 7.4. The MAPS manual suggests music or recordings from the sessions, breathing techniques, drawing, singing, dancing, yoga, exercise and time in nature (Mithoefer, 2017). Yaden and colleagues (2022) add behavioural activation and scheduling valued activities, because insights gained in the dosing session “do not automatically impart ability or reduce barriers” to acting on them. For psychotherapy with people who use psychedelics, the Psychedelic Harm Reduction and Integration model of Gorman and colleagues (2021) draws on mindfulness-based, psychodynamic, psychedelic-assisted and harm reduction approaches (Bathje et al., 2022). The tabs group common practices by facet.
Journaling, written accounts of the session, dream notes, continued psychotherapy and reviewing intentions (Mithoefer, 2017; Bathje et al., 2022).
Breathing practice, yoga, dance, exercise and rest; within the MAPS method, focused bodywork with consent (Mithoefer, 2017).
Reflecting on values and meaning, with the person’s own interpretation respected (Murphy et al., 2022; Mithoefer, 2017).
Sharing with chosen, trusted people, group sharing and service; in group programs the group itself is a place of integration (Mithoefer, 2017; Dames et al., 2025).
Turning insight into planned change through behavioural activation, valued activities and new routines (Yaden et al., 2022).
Evidence on specific practices is at an early stage. A 2023 review found that integration models and methods had yet to be tested in studies of their effectiveness (Greń et al., 2023), a 2026 scoping review described measures of post-session integration as still undervalidated (Mele & Federici, 2026), and the trials in this lesson delivered integration as part of a package that they did not take apart. Integration is therefore best described as reasoned clinical practice with limited direct evidence (Section 1, 3.1 What Trials Can and Cannot Tell Us About the Therapy), and research in this area is evolving.
The morning after his first dosing session in a hypothetical authorized trial, a participant says he is embarrassed: he shouted, cried for a long time and said things about his brother he has never said aloud. His therapists begin with an open invitation, say that strong emotion was expected and ask what stands out for him, offering no interpretation of what he said. As the protocol requires, they ask directly about thoughts of harming himself and record his answer. Together they plan a short daily call, ten minutes of writing each evening, a walk outdoors, and waiting before raising the subject with his brother. They remind him that more may come in waves and that he can call the team at any time, and they will review before the second dose whether anything argues against it (Mithoefer, 2017).
8.3 Measuring Outcomes
Clinical outcome measures track the condition being treated and the person’s safety (Lessons 8 to 10); integration measures describe the process of making use of an experience. Table 7.4 lists measures used in the protocols in this lesson.
Table 7.4. Measures used in the protocols discussed in this lesson: what each measures, who completes it, and an example of its use.
| Measure | What it measures | Completed by | Example of use |
|---|---|---|---|
| Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | PTSD symptom severity | Clinician, by interview | MAPP1 primary outcome, by blinded independent raters (Mitchell et al., 2021) |
| Quick Inventory of Depressive Symptomatology (QIDS-SR-16) | Depression severity | The person | Imperial trial primary outcome (Murphy et al., 2022) |
| PHQ-9, GAD-7, PCL-5 and B-IPF | Depression, anxiety, PTSD symptoms, work and life functioning | The person | Roots to Thrive intake and discharge (Dames et al., 2022, 2025) |
| Columbia Suicide Severity Rating Scale (C-SSRS) | Suicidal thoughts and behaviour | Clinician | Each MAPP1 dosing session and throughout (Mitchell et al., 2021; Mithoefer, 2017) |
| Integration Engagement Scale and Experienced Integration Scale | Reflection and application; feeling settled, harmonized and improved | The person | Validated in online samples of 232 and 315 people in the United States (Frymann et al., 2022) |
| Persisting Effects Questionnaire | Lasting changes in attitudes, relationships, behaviour and spirituality | The person | Developed by Griffiths and colleagues (2006) (Frymann et al., 2022) |
Two features of the table matter for practice. The first is who rates: MAPP1 collected safety data through site therapists, which may have limited blinding (Mitchell et al., 2021), and a clinic that relies on its own therapists’ judgements, or on participants’ reports at the end of a hopeful program, may overestimate benefit. The second is what an integration scale shows: the two integration scales had high internal consistency (Cronbach’s alpha of 0.90 for the Integration Engagement Scale and 0.92 for the Experienced Integration Scale), but they were validated in a culturally and demographically limited online sample in the United States, and they measure engagement with an experience, which differs from recovery from an illness (Frymann et al., 2022).
8.4 Knowing When to Refer or Escalate Care
Problems often surface in integration. Health Canada expects check-in visits after dosing because mental health may worsen (Health Canada, 2022), the MAPS manual notes that suicidal thoughts may increase temporarily after sessions in people with PTSD (Mithoefer, 2017), and serious adverse events, including suicidal behaviour, have occurred in trials (Lesson 6). The accordion lists situations that call for referral or escalation.
Assess with a structured tool such as the C-SSRS, increase contact, involve the responsible physician or psychiatrist, and use emergency services when there is immediate danger; crisis lines such as 9-8-8 belong in the safety plan (Mithoefer, 2017).
Severe distress that persists after a period of stabilization calls for the steps in Section 3, including, only in extreme conditions, hospital admission (Mithoefer, 2017).
Unusual beliefs, disorganized thinking, elevated mood with a decreased need for sleep (National Institute of Mental Health, 2025), or perceptual changes that persist call for psychiatric assessment (Lessons 5 and 6).
Problematic use of alcohol or other drugs calls for referral to substance use services, which HSCI 402 develops.
Medical questions, medication changes and diagnosis belong to physicians and nurse practitioners; the British Columbia Association of Clinical Counsellors (2024) reminds members that they are not medical professionals.
People without ongoing therapy may need a referral when scheduled sessions end, which the MAPS manual asks therapists to offer where warranted (Mithoefer, 2017).
9.1 The Legal Limits of Preparation and Integration Support in Canada
Clients sometimes ask a counsellor, nurse, psychologist, social worker or physician to help them prepare for a planned experience or to help them afterward. The course’s practice standard is that clinicians support the use of controlled psychedelics only through authorized routes; the legal reasons follow.
Legal information, not legal advice
This part describes general features of Canadian law as of October 2026 so that readers can recognize when a situation raises a legal question. It is not legal advice, which applies the law to a person’s particular circumstances. A practitioner facing one of these situations should consult a lawyer and the regulatory college or association that governs their practice.
9.1.1 Two Provisions
The statutory text
Controlled Drugs and Substances Act, subsection 4(1): “Except as authorized under the regulations, no person shall possess a substance included in Schedule I, II or III.”
Criminal Code, subsection 21(1): “Every one is a party to an offence who (a) actually commits it; (b) does or omits to do anything for the purpose of aiding any person to commit it; or (c) abets any person in committing it.”
Schedule III of the Controlled Drugs and Substances Act lists LSD, DMT, psilocin, psilocybin and mescaline (peyote excluded), and Schedule I lists MDMA among the amphetamines and ketamine among the derivatives of phencyclidine (current to 30 September 2026). Possession of a Schedule III substance carries up to three years’ imprisonment on indictment, and of a Schedule I substance up to seven (subsections 4(3) and 4(6)). Ketamine can be used lawfully in therapy because it is marketed in Canada as an anaesthetic that physicians can prescribe off-label (Drug Product Database, 2026). Health Canada states that the production, sale and possession of magic mushrooms are illegal unless it has authorized them, and that no approved therapeutic product contains psilocybin (Health Canada, 2025).
9.1.2 How the Provisions Combine
Section 21 makes a person a party to an offence, and so liable to conviction for it, if they do anything for the purpose of aiding another person to commit it or if they abet it, which in ordinary usage means encouraging or supporting it. A person who uses psilocybin obtained outside an authorized route will have possessed it. A professional who, before that use, holds preparation sessions for it, advises on how to use it, books an integration session as part of the plan, or attends the session to make it safer may therefore be at risk of being treated as having aided or abetted the possession. Section 21 contains no exception for help given to reduce harm, and the Supreme Court of Canada has held that “purpose” in paragraph 21(1)(b) is essentially synonymous with intention, that the helper need not desire that the offence be committed, and that the helper must know that the other person intends to commit it (R v Briscoe, 2010 SCC 13). Whether a particular act meets the legal test depends on its facts, which is one reason why legal advice is needed in any real case.
Support for someone who seeks help with an experience that has already happened, and who has no plan to use again, differs in one respect. Help given after a possession has ended does not appear to be given “for the purpose of aiding” it, and helping people with distress after past substance use is a familiar part of mental health care, although this is an interpretation of the section’s wording that a court could read differently. The analysis changes if the conversation turns to planning a future use, and colleges and associations may set their own expectations in either case.
9.1.3 The Changing Context
British Columbia’s exemption that removed criminal penalties for adults possessing up to 2.5 grams in total of opioids, cocaine, methamphetamine and MDMA ran from 31 January 2023 to 31 January 2026 and never covered psilocybin (Toward the Heart, 2026; BC Centre for Disease Control, n.d.). As of October 2026, ibogaine and 5-MeO-DMT were not named in the schedules, although the Food and Drugs Act still regulates the sale of any drug; Lesson 11 develops these questions, with unlicensed storefronts and retreats.
9.1.4 Professional Rules and Authorized Routes
Guidance from the British Columbia Association of Clinical Counsellors (2024) states that Registered Clinical Counsellors cannot procure, prescribe, dispense or administer psychedelics; that with appropriate training they may prepare people, support sessions under medical supervision and facilitate integration; and that they should offer these services only to sanctioned clinical trials or programs. In Alberta, a practice guideline approved in June 2025 states that social workers may provide psychedelic-assisted psychotherapy only through a licensed psychedelic treatment service provider and are not authorized to procure or administer psychedelic substances (Alberta College of Social Workers, 2025).
As of October 2026, there are four authorized routes, which Lesson 11 describes in detail: clinical trials authorized by Health Canada, the Special Access Program, exemptions under subsection 56(1), and ketamine-assisted psychotherapy with lawfully prescribed ketamine, which in Alberta requires a licensed provider (Government of Alberta, 2025). Practitioners have again been able to request restricted drugs such as psilocybin and MDMA through the Special Access Program since amendments published on 5 January 2022 (Canada Gazette, 2022), with requests assessed case by case for patients whose conventional treatments have failed or are unsuitable or unavailable (Health Canada, 2023). Since 1 October 2026 the program has operated under the Controlled Substances Regulations, which allow a practitioner named in a letter of authorization to administer the drug and the patient to possess it (SOR/2025-242, ss. 6(1)(g) and 131(2)). Subsection 56(1) allows the Minister to exempt a person or class of persons “if, in the opinion of the Minister, the exemption is necessary for a medical or scientific purpose or is otherwise in the public interest”; the exemptions granted from August 2020 allowed patients to use psilocybin and health care practitioners to use it in training (Lesson 11). Interactive 7.4 applies these distinctions.
All situations are hypothetical. Choose a category for each, then select Check my answers. The feedback is legal information as of October 2026, not legal advice.
A hypothetical client tells a registered social worker in British Columbia that she plans to take psilocybin bought online next month and asks for “a couple of prep sessions and a debrief afterward”. In four sentences, describe the legal position as information, what the social worker can offer, and what they should seek before deciding.
Suggested answer: Unauthorized possession of psilocybin is an offence under subsection 4(1) of the Controlled Drugs and Substances Act, and a person who aids or abets it can be a party under subsection 21(1) of the Criminal Code, so preparation for this planned use, or a debrief arranged in advance, may expose the social worker to legal risk. The social worker can continue to support her mental health, explore what she hopes psilocybin will do, and discuss treatments, including whether a physician might seek a trial place or a Special Access Program authorization for her. Help with an experience that has already happened, with no planned use, would be closer to ordinary mental health care. Before deciding, the social worker should obtain legal advice and consult their college.
Using the Roots to Thrive protocol (Dames et al., 2025) and evaluations (Dames et al., 2022; Tsang et al., 2023) described in Sections 1 and 3, (a) map the program onto the four phases of Figure 7.1; (b) give one way its group format differs from the individual model in Health Canada’s 2022 expectations for trials, and say why those expectations do not apply to it directly; (c) state what its evaluations allow you to conclude and what they do not; and (d) choose one measure from Table 7.4 that would strengthen a future evaluation.
Suggested answer: (a) Referral, screening and intake measures are screening; early groups, the education session, the physician consultation and the touch-preference form are preparation; the three ketamine sessions are dosing; the small groups, integration meetings, alumni community and discharge note are integration. (b) Facilitators are shared at about one per three or four participants, while the trial expectations assume two therapists per participant; those expectations govern trials of restricted drugs, and the program is a clinical service using a prescribed medicine. (c) Participants reported large improvements and ketamine was well tolerated, but without randomized controls the evaluations cannot show what caused the change, how much ketamine contributed or whether results apply beyond health care workers. (d) Blinded independent ratings, such as the CAPS-5, would reduce the bias of end-of-program self-report.
Integration turns an experience into change, its outcomes need independent measurement, and in Canada preparation and integration connected to a planned use of a controlled psychedelic belong inside authorized routes. Lessons 8 to 10 ask whether this process improves depression, distress in serious illness, PTSD and addiction.
Key Takeaways
- 8.1 Integration is a process in which a person revisits and actively makes sense of a psychedelic experience and translates it into changes in daily life. Bathje and colleagues synthesized ten models published since 2017 into a Synthesized Model of Integration with six facets: mind and emotion, the body, spirit and meaning, relationships and community, lifestyle and action, and the natural world. The model is conceptual, and its authors acknowledge that it needs further research.
- 8.2 Protocols hold a first integration session soon after the dose, the next morning in MAPP1 and the Imperial trial, followed by further sessions and contact over the following weeks; the person’s experience sets the agenda and therapists keep their own interpretations to a minimum. Recommended practices span all six facets, from journaling and breathing to behavioural activation and time in nature. Evidence on specific practices is at an early stage, so integration is best described as reasoned clinical practice with limited direct evidence.
- 8.3 Clinical measures such as the CAPS-5, the QIDS-SR-16 and the C-SSRS track the condition being treated and the person’s safety, while integration scales describe engagement with an experience. Who rates matters: ratings by the treating therapists, or self-reports at the end of a hopeful program, may overestimate benefit. The 2022 integration scales were validated in limited online samples in the United States and measure engagement, which differs from recovery from an illness.
- 8.4 Suicidal thoughts or behaviour, persistent worsening, distress that does not settle, signs of psychosis or mania, persistent perceptual changes, substance use concerns and needs beyond the therapist’s scope call for referral or escalation. Worsening is assessed and never assumed to be progress, and people without ongoing therapy may need a referral when the scheduled sessions end.
- 9.1 As legal information, possession of a scheduled psychedelic without authorization is an offence under subsection 4(1) of the Controlled Drugs and Substances Act, and subsection 21(1) of the Criminal Code makes a party to an offence anyone who aids or abets it, with no exception for help given to reduce harm. A professional who prepares a client for, or arranges integration as part of, a planned unauthorized use may therefore be at legal risk, while help with a past experience and no planned use is closer to ordinary mental health care. As of October 2026, the authorized routes are trials authorized by Health Canada, the Special Access Program, exemptions under subsection 56(1) and ketamine-assisted psychotherapy with lawfully prescribed ketamine.
Reflection
A hypothetical Registered Clinical Counsellor in British Columbia has two new clients. Client 1 used psilocybin at a festival a year ago, has had panic attacks since, and does not intend to use psychedelics again. Client 2 plans to take MDMA with a partner next month and asks for preparation sessions and an integration session afterward. Subsection 4(1) of the Controlled Drugs and Substances Act prohibits possession of a substance in Schedule I, II or III except as authorized; subsection 21(1) of the Criminal Code makes a party to an offence anyone who does anything for the purpose of aiding, or who abets, its commission; British Columbia’s exemption that covered small amounts of MDMA ended on 31 January 2026; and the 2024 BC Association of Clinical Counsellors guidance says counsellors should offer psychedelic-related services only to sanctioned trials or programs. Explain, as legal information, how the two situations differ and what the counsellor can appropriately offer each client, and say when the counsellor should refer Client 1 to other care.
Client 1 is seeking help with an experience that has already happened. Help given now does not appear to be given for the purpose of aiding a possession that is over, so treating her panic attacks is ordinary mental health care, within the counsellor’s training and standards, although this is an interpretation of the section’s wording that a court could read differently. The counsellor can assess the panic attacks, offer evidence-based treatment for anxiety and help her make sense of the experience. Referral is needed if she reports suicidal thoughts, persistent perceptual changes, signs of psychosis or mania, or if symptoms worsen or do not respond, in which case a physician or psychiatrist should assess her.
Client 2 is asking for support connected to a planned possession of MDMA, a Schedule I substance. Since the British Columbia exemption ended in January 2026, that possession would be unauthorized, and preparation sessions or an integration session arranged in advance could be treated as aiding or abetting it. The BCACC guidance also directs counsellors to offer such services only within sanctioned trials or programs. The counsellor can continue to support Client 2’s mental health, explore what he hopes MDMA will do and discuss treatments, including authorized routes through a physician. This is general legal information; before deciding, the counsellor should obtain legal advice and consult their professional body.
Minimum 20 characters required.
Question 1: Which definition of integration did Bathje, Majeski and Kudowor (2022) propose?
Question 2: What do the Integration Engagement Scale and the Experienced Integration Scale measure?
Question 3: As legal information, why might preparation sessions for a client’s planned use of unauthorized psilocybin put a regulated professional in Canada at legal risk?
Question 4: Which situation falls within an authorized route in Canada as of October 2026?
Final Assessment
Bringing It All Together
This lesson has followed psychedelic-assisted therapy through its four phases. The trial models described here, from the inner-directed MAPS approach to psychological support at Johns Hopkins and the Accept, Connect, Embody model at Imperial College London, all give a high dose on one or a few occasions inside a course of psychotherapy, with preparation before and integration after. Ketamine-assisted psychotherapy and group programs such as Roots to Thrive in Nanaimo show what practice looks like where a medicine marketed in Canada as an anaesthetic can be prescribed off-label, and Calculator 7.1 showed how much the staffing of a protocol shapes its cost and reach.
Most of what keeps a dosing session safe is settled beforehand, while the person is sober: the alliance, intentions, honest psychoeducation, consent to touch and recording, and a safety plan. On the day, a team of at least two therapists offers non-directive support, follows the protocol for monitoring, and records what happens in timed, factual notes. Integration then helps the person make sense of the experience and act on it, with outcomes measured independently and clear triggers for referral.
Two limits run through the lesson. The contribution of the therapy, as distinct from that of the drug, remains insufficiently understood, as a 2026 meta-analysis concluded (Florineth et al., 2026), and research on each component of the process is at an early stage and evolving. And in Canada, preparation and integration connected to a planned use of a controlled psychedelic belong inside authorized routes, because party liability under the Criminal Code can attach to help given for unauthorized possession.
Key Takeaways from this lesson
- Contemporary psychedelic-assisted therapy follows four phases, screening, preparation, one or a few supervised dosing sessions, and integration, and the non-drug sessions are part of the treatment.
- Many recent trials follow the high-dose psychedelic tradition, with non-directive support during sessions (Yaden et al., 2022), while the psycholytic tradition used lower doses with more active therapy during the drug state. The MAPS manual describes a largely non-directive method in which therapists follow the participant’s process and the participant’s inner healing intelligence is treated as the source of healing, an assumption that Brennan and Belser (2022) noted had yet to be tested; psilocybin trials used similar psychological support or the Accept, Connect, Embody model, and ketamine-assisted psychotherapy and group programs such as Roots to Thrive use a medicine that can be prescribed in Canada.
- Because placebo-controlled trials give both arms the same therapy, they estimate the drug’s added effect and cannot show what the therapy itself contributes.
- Group programs such as Roots to Thrive need far fewer clinician hours per participant than individual trial protocols, but the published evaluations of the Roots to Thrive ketamine program are non-randomized, and its outcome reports concern health care workers.
- Preparation builds the alliance, takes a history, helps the person form intentions held loosely and explains honestly what the session may involve, without promising an outcome.
- Under the course’s practice standard, decisions about touch and recording are made while the person is sober, and during the session consent can be confirmed, narrowed or withdrawn but never widened; the MAPS manual (section 3.4) is more permissive, since it allows touch that the participant asks for or initiates during a session. A safety plan agreed in advance covers the session day, the night after it and the following weeks.
- In Canadian trials a dosing session is expected to have at least two therapists and a physician on site, with a protocol for monitoring blood pressure, heart rate and mental state and a discharge decision based on the team’s assessment of stability.
- Integration is a process of revisiting, making sense of and applying an experience; its practices are well reasoned, but a 2023 review found that integration models and methods had yet to be tested for effectiveness (Greń et al., 2023), and its outcomes need independent measurement. Suicidal thoughts, persistent worsening, distress that does not settle and signs of psychosis or mania call for referral or escalation, and worsening is never assumed to be progress.
- As legal information, a regulated professional in Canada who gives preparation or integration connected to a planned unauthorized possession of a scheduled psychedelic may be a party to that offence under section 21 of the Criminal Code.
Core Concepts Reviewed
Section 1: the four phases; psycholytic and psychedelic traditions; non-directive support and inner healing intelligence; basic support and added-therapy models; the Accept, Connect, Embody model; ketamine-assisted psychotherapy; the community of practice model; and clinician hours per participant.
Section 2: the therapeutic alliance; history taking; intentions; psychoeducation; consent obtained while sober; nurturing touch, focused bodywork and the stop word; consent to recording; and safety agreements.
Section 3: the session day; setting, music and eyeshades; the co-therapist team and medical oversight; non-directive support and its limits; monitoring; discharge; and documentation.
Section 4: definitions and models of integration; integration practices; clinical and integration measures; referral triggers; party liability under section 21 of the Criminal Code and possession under section 4 of the Controlled Drugs and Substances Act; and authorized routes.
The final reflection asks you to bring the four phases together in an outline for a hypothetical authorized trial in British Columbia.
Reflection
A hypothetical research team plans a Health Canada-authorized trial of psilocybin-assisted therapy for depression in British Columbia, with two dosing sessions three weeks apart. Draft an outline of the therapeutic process for one participant, covering (a) preparation: how many sessions, with whom, and what they cover, including consent to touch and to recording; (b) the dosing day: team, setting, monitoring and discharge; (c) integration: timing, practices, measures and the situations that would trigger referral; and (d) one limitation of the evidence that the team should state honestly in its consent materials. Justify each choice with a published protocol or Canadian requirement from this lesson.
(a) Preparation: two or three meetings, totalling about 5 to 8 hours as in the Imperial and Hopkins trials, with the same two therapists who will run the dosing sessions, as Health Canada expects. They cover the person’s history and reasons for treatment, intentions, what the session may involve, breathing practice, and written consent while sober, including the types of touch accepted, how it is offered, the stop word, and whether video recording is accepted, with its purpose, review and retention.
(b) Dosing day: two therapists present throughout and a physician on site; a private, comfortable room with eyeshades, headphones and a prepared playlist; blood pressure, heart rate and mental state recorded at set times, as in the Hopkins schedule; discharge only after the team judges the person stable, with transport arranged.
(c) Integration: a session the next morning, weekly contact, and a final visit, using practices such as journaling, valued activities and time in nature. Outcomes are rated by blinded independent raters, with the C-SSRS at each visit. Suicidal thoughts, persistent worsening, signs of psychosis or mania, or distress that does not settle trigger referral to the trial physician or psychiatrist.
(d) Consent materials should state that the contribution of the therapy, as distinct from that of the drug, remains insufficiently understood, as a 2026 meta-analysis concluded (Florineth et al., 2026), and that the evidence is limited in size, blinding and duration.
Minimum 30 characters required.
Final Knowledge Assessment
Question 1: A protocol gives three 8-hour MDMA sessions and twelve 90-minute non-dosing sessions, all with the same two therapists. Which pair of figures per participant is correct?
Question 2: Which feature do the MAPS approach, the Hopkins psychological support model and the Accept, Connect, Embody model share?
Question 3: Why does the Imperial psilocybin and escitalopram trial not show whether the Accept, Connect, Embody model itself helps?
Question 4: Health Canada (2022) expects consent to touch to be obtained before dosing as well as in the therapeutic moment. How does this fit the practice standard of consent obtained while sober?
Question 5: During a hypothetical session, a participant asks what a recurring image means. Which response follows the MAPS manual?
Question 6: Which pairing of protocol and monitoring practice is correct?
Question 7: What did Tsang and colleagues (2023) report from their chart review of the Roots to Thrive program?
Question 8: Which statement about the published evaluations of the Roots to Thrive ketamine program is accurate as of October 2026?
Question 9: Which integration practice did Yaden and colleagues (2022) recommend, and why?
Question 10: MAPP1 collected efficacy data through blinded independent raters and safety data through site therapists. What does Section 4 conclude from this?
Question 11: Which situation in integration calls for referral or escalation of care?
Question 12: In which schedules of the Controlled Drugs and Substances Act are psilocybin and MDMA listed?
Question 13: Why did British Columbia’s 2023 to 2026 decriminalization exemption not change the legal position of preparation for a planned use of psilocybin?
Question 14: According to the 2024 guidance of the BC Association of Clinical Counsellors, what may a Registered Clinical Counsellor do with appropriate training?
Question 15: Which statement best summarizes the evidence on the therapy component of psychedelic-assisted therapy as of 2026?
Glossary: Key Terms, People & Frameworks
📚 Reference page, available throughout the lesson
Terms, frameworks and people introduced in this lesson on the therapeutic process of psychedelic-assisted therapy.